Psoriasis often involves joint symptoms known as psoriatic arthritis (PsA) in about 20% of cases. Effective treatments must target both skin and joint symptoms. While biologic therapies have been a breakthrough for unresponsive cases, Janus Kinase inhibitors (JAKis) have recently emerged as promising oral treatments. This review analyzed randomized-controlled trials (RCTs) of JAKis approved by the European Medicines Agency and FDA for plaque psoriasis and PsA to understand their effects on psoriasis.

The review found that three JAKis— tofacitinib, upadacitinib, and deucravacitinib—showed efficacy in treating psoriasis and PsA. Tofacitinib significantly improved both skin and joint symptoms in several phase 2 and 3 RCTs. Deucravacitinib, with its TYK2 selectivity, proved effective with a favorable safety profile. Upadacitinib, tested in two phase 3 RCTs, improved PsA symptoms and showed potential for skin treatment. JAKis provide a new treatment option for psoriasis, especially for patients with concurrent PsA, by effectively managing inflammation and improving quality of life.

Reference: Furtunescu AR, Georgescu SR, Tampa M, Matei C. Inhibition of the JAK-STAT Pathway in the Treatment of Psoriasis: A Review of the Literature. Int J Mol Sci. 2024;25(9):4681. doi: 10.3390/ijms25094681.